Last reviewed · How we verify
NCT06757530
Radiomics Model for Assessing Lymph Node Status in cN0 Patients withHNSCC
trial testing AI in HNSCC in 700 participants. Completed in 15 April 2025.
15 April 2025
Quick facts
| Lead sponsor | First Affiliated Hospital of Chongqing Medical University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 700 |
| Start date | 27 November 2024 |
| Primary completion | 15 April 2025 |
| Estimated completion | 15 April 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- AI — full drug profile →
Conditions studied
- HNSCC — all drugs for HNSCC →
Sponsor
First Affiliated Hospital of Chongqing Medical University
Who can join
Adults 18 to 89, any sex, with HNSCC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Occult lymph node metastasis (LNM) remains one of the most critical and challenging aspects of managing head and neck squamous cell carcinoma (HNSCC). Defined as the presence of metastatic disease in lymph nodes that are clinically undetectable through routine imaging or physical examination, occult LNM has profound implications for treatment planning, prognosis, and overall patient management. In HNSCC, accurate detection and prediction of occult LNM are crucial as they significantly influence decisions regarding the extent of neck dissection, the need for adjuvant therapies, and the overall therapeutic strategy. Undiagnosed or underestimated LNM can result in inadequate treatment, increasing the risk of locoregional recurrence and poor survival outcomes.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Habitat radiomics predicts occult lymph node metastasis and uncovers immune microenvironment of head and neck cancer.
Chen X, Jiang H, Pan M, Feng C, et al · · 2025 · cited 8× · PMID 40312725 · DOI 10.1186/s12967-025-06474-7
Verify or expand the search:
- PubMed search for NCT06757530
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of AI
Trials testing the same drug.
- NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting
- NCT07462351 — System-integrated Point-of-Care Ultrasound in Breast Cancer Screening · NA · recruiting
- NCT07084779 — Investigation of Impact of AI on Prostate Cancer Workflow · NA · recruiting
- NCT06741657 — A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Diff · Phase 1 · completed
- NCT06931782 — AI in Respiratory Disease Prevention, Diagnosis, and Triage · NA · enrolling by invitation
Other recruiting trials for HNSCC
Currently open trials in the same condition.
- NCT07035249 — DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07081984 — Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors · Phase 1 · recruiting
- NCT07182149 — A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors · Phase 1 · recruiting
- NCT07106827 — A Study of GV20-0251 in Advanced or Refractory Solid Tumors · Phase 1 · recruiting
- NCT07136545 — A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metas · Phase 1, PHASE2 · recruiting
Other First Affiliated Hospital of Chongqing Medical University trials
Trials by the same sponsor.
- NCT07369713 — Efficacy and Safety of Accelerated Intermittent Theta-burst Stimulation (a-iTBS) in Adolescents With Depressive Disorder · NA · not yet recruiting
- NCT07499323 — Talquetamab in Patients With Refractory Generalized Myasthenia Gravis · NA · not yet recruiting
- NCT07409870 — An Integrated Multi-omics Study on the Molecular Mechanisms of Ureteral Stricture · not yet recruiting
- NCT07324473 — Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired R · Phase 2 · not yet recruiting
- NCT07203144 — Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06757530 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Chongqing Medical University
- Last refreshed: 28 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06757530.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing